You just read:

Global Blood Therapeutics Announces New Clinical Data that Continue to Support Safety and Efficacy Profile of GBT440 as a Potentially Disease-Modifying Therapy for Sickle Cell Disease

News provided by

Global Blood Therapeutics, Inc.

Jun 10, 2016, 02:30 ET